Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Oct 21, 2010Latest innovation in plastic biliary stent technology includes features for enhanced deliverability, efficiency and procedural control
Boston Scientific Corporation (NYSE: BSX) today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration and CE...
-
Oct 19, 2010
Boston Scientific Corporation (NYSE: BSX) today announced financial results for the third quarter ended September 30, 2010, as well as guidance for...
-
Oct 13, 2010Major advance in guidewire technology for challenging peripheral interventions
Boston Scientific Corporation (NYSE: BSX) today announced the global launch of its Journey™ Guidewire, an innovative 0.014" guidewire designed for use in...
-
Oct 7, 2010
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the third quarter ended September 30,...
-
Sep 28, 2010MADIT II eight-year outcomes analysis shows that one life is saved for every eight patients who receive an ICD
Boston Scientific Corporation (NYSE: BSX) today welcomed the publication of an analysis of long-term data from the MADIT II clinical trial in the...
-
Sep 25, 2010
Boston Scientific Corporation (NYSE: BSX) today announced three-year follow-up data from the HORIZONS-AMI trial. The trial, sponsored by the...
-
Sep 22, 2010Company presents one-year clinical data at TCT on its platinum chromium paclitaxel-eluting coronary stent from PERSEUS trial
Boston Scientific Corporation (NYSE: BSX) today announced results from an analysis of 1,166 patients from its PERSEUS clinical program comparing...
-
Sep 22, 2010Results of TAXUS ATLAS clinical program presented at TCT
Boston Scientific Corporation (NYSE: BSX) today announced comprehensive data from the TAXUS ATLAS clinical program, a series of global,...
-
Sep 21, 2010Nine-month results from PLATINUM clinical program presented at TCT
Boston Scientific Corporation (NYSE: BSX) today announced data from its PLATINUM QCA study, which is designed to evaluate the Company's PROMUS Element™...
-
Sep 21, 2010
Boston Scientific Corporation (NYSE: BSX) today announced that its PROMUS® Element™ Everolimus-Eluting Coronary Stent System has received CE...